Exosome as the Prognostic and Predictive Biomarker in EBC Patients

Development of a Prognostic and Predictive Biomarker for Locally Advanced Breast Cancer Patients Treated With Neoadjuvant Chemotherapy Using Exosome

Status

Active, not recruiting

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05955521

Enrollment

200

Registered

2023-07-21

Start date

2021-05-01

Completion date

2028-07-01

Last updated

2023-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HER2-positive Breast Cancer, Triple Negative Breast Cancer

Brief summary

This study is the experimental study for serial ctDNA and exosome evaluation in EBC patients

Interventions

PROCEDUREexosome and ctDNA evaluation

Serial exosome and ctDNA evaluation during follow up period between neoadjuvant chemotherapy and surveillance after curative surgery.

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

SCREENING

Masking

NONE

Eligibility

Sex/Gender

FEMALE

Healthy volunteers

Yes

Inclusion criteria

* Early breast cancer * Planned neoadjuvant chemotherapy * Triple negative breast cancer or HER2-positive breast cancer

Exclusion criteria

* Stage IV breast cancer * Hormone receptor positive breast cancer

Design outcomes

Primary

Measure	Time frame	Description
Prognostic biomarker for EBC	60 months	Positive predictive value of ctDNA/Exosome for BC recurrence

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026